Literature DB >> 15035022

HIV-1 dynamics in vivo: implications for therapy.

Viviana Simon1, David D Ho.   

Abstract

The advent of potent combination antiretroviral therapy has been an important breakthrough in the treatment of HIV-1 infection, resulting in marked reductions in HIV-1-related morbidity and mortality. Antiretroviral therapy has also provided researchers with a powerful tool to perturb the equilibrium of viral production and viral clearance, allowing them to dissect the underlying dynamics that control the pathogenesis of AIDS. Here, we review our current understanding of the sources of HIV-1 production, the estimates for the virion and the host-cell half-lives, and the pathways of virion trafficking and clearance. We also discuss the obstacles that result from the ability of HIV-1 to remain dormant for a prolonged period of time in a subset of long-lived cells, despite an apparently effective antiretroviral treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15035022     DOI: 10.1038/nrmicro772

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  77 in total

Review 1.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

2.  Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.

Authors:  Ernesto J Muñoz-Elías; Juliano Timm; Tania Botha; Wai-Tsing Chan; James E Gomez; John D McKinney
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility.

Authors:  Libin Rong; Michael A Gilchrist; Zhilan Feng; Alan S Perelson
Journal:  J Theor Biol       Date:  2007-04-19       Impact factor: 2.691

4.  Divergent patterns of recent retroviral integrations in the human and chimpanzee genomes: probable transmissions between other primates and chimpanzees.

Authors:  Patric Jern; Göran O Sperber; Jonas Blomberg
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 5.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

6.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

7.  HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes.

Authors:  Cinzia Nobile; Dominika Rudnicka; Milena Hasan; Nathalie Aulner; Françoise Porrot; Christophe Machu; Olivier Renaud; Marie-Christine Prévost; Claire Hivroz; Olivier Schwartz; Nathalie Sol-Foulon
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 8.  Nano/Microfluidics for diagnosis of infectious diseases in developing countries.

Authors:  Won Gu Lee; Yun-Gon Kim; Bong Geun Chung; Utkan Demirci; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2009-11-30       Impact factor: 15.470

9.  A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.

Authors:  Masayuki Amano; Pedro Miguel Salcedo-Gómez; Rui Zhao; Ravikiran S Yedidi; Debananda Das; Haydar Bulut; Nicole S Delino; Venkata Reddy Sheri; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.